EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Survival of Intravenous Edaravone–Treated Patients With ALS : Evidence From Administrative Claims Analyses

Benjamin Rix Brooks iD, James D Berry, Malgorzata Ciepielewska

Muscle & Nerve · 2026

DOI: 10.1002/mus.70041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Benjamin Rix Brooks und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Planning LLC, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Edaravone, Amyotrophic Lateral Sclerosis, Free Radical Scavengers. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mitsubishi Tanabe Pharma America, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Randomized controlled trials remain the cornerstone of evidence generation in amyotrophic lateral sclerosis (ALS), yet their inherent challenges, including disease rarity, heterogeneity, and limited validated biomarkers, highlight the need for complementary clinical evidence. This exploratory, retrospective study assessed overall survival in patients with ALS treated with intravenous (IV) edaravone using data from a large United States administrative claims database of patients enrolled from August 2017 to March 2020. Patients receiving IV edaravone ( n = 318) were propensity score matched 1:1 with controls not treated with IV edaravone ( n = 318), adjusting for 11 covariates. Median overall survival was 29.5 versus 23.5 months for the edaravone‐treated group compared to controls, with a 27% reduced risk of death observed in the treated cohort ( p = 0.005). These findings, together with existing data from the pivotal phase 3 Study MCI186‐19 of IV edaravone, contribute to the growing body of literature suggesting a dual benefit of edaravone on both function and survival in ALS, offering critical insights for clinicians, patients, and payers navigating ALS treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EdaravoneAmyotrophic Lateral SclerosisFree Radical ScavengersHumansFemaleRetrospective StudiesMaleAgedMiddle AgedAdministration, IntravenousUnited StatesTreatment Outcome

Stichwörter der Autor:innen

ALSadministrative claimsamyotrophic lateral sclerosisedaravoneefficacysurvival

Substanzen

EdaravoneFree Radical Scavengers

Autor:innen und Institutionen

  • Clinical Trials Planning LLC, Charlotte, North Carolina, USA.
  • Healey Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.

ORCID-Profile: Benjamin Rix Brooks

Förderung

  • Mitsubishi Tanabe Pharma America, Inc.

Zitieren

APA

Brooks, B. R., Berry, J. D., & Ciepielewska, M. (2026). Survival of Intravenous Edaravone–Treated Patients With ALS : Evidence From Administrative Claims Analyses. Muscle & Nerve. https://doi.org/10.1002/mus.70041

Vancouver

Brooks BR, Berry JD, Ciepielewska M. Survival of Intravenous Edaravone–Treated Patients With ALS : Evidence From Administrative Claims Analyses. Muscle & Nerve. 2026. doi:10.1002/mus.70041

BibTeX
@article{Brooks2026,
  author = {Brooks, Benjamin Rix and Berry, James D and Ciepielewska, Malgorzata},
  title = {Survival of Intravenous Edaravone–Treated Patients With ALS : Evidence From Administrative Claims Analyses},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70041}
}
Kostenlos starten →